Connecticut is currently home to 1246 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Telehealth Treatment for Opioid Use Disorders
NCT05832879
Recruiting
This study aims to use an Opioid Use Disorder (OUD) Telehealth Platform to reduce overdose events. This telehealth platform will be pilot tested to evaluate its preliminary efficacy in terms of motivating engagement in medications for OUD (MOUD), as well as its feasibility, acceptability and satisfaction to both first responders/providers and participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Opioid Use Disorder
Register for Updates
LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
NCT05786417
Recruiting
To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with symptomatic Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).
Gender:
ALL
Ages:
65 years and above
Trial Updated:
02/05/2025
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Angina, Stable Ischemic Heart Disease
Register for Updates
SHAPE Test for Preoperative Risk Stratification
NCT05743673
Recruiting
Primary Objective Characterizing precise functional capacity in surgical patients is critical for risk stratification and identification of patients at high risk for perioperative complications. The primary objective for the study is to evaluate the feasibility of effective subject recruitment of an FDA-approved simplified cardiopulmonary exercise testing apparatus in adults \>60 years old prior to moderate to high-risk surgery. In addition, by development of a validation cohort of older adults,... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
02/05/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Perioperative/Postoperative Complications, Aerobic Capacity
Register for Updates
CRUSH PAD: Real-world Outcomes Following Use of Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions
NCT05145478
Recruiting
The primary goal of the study is to obtain effect size data on the use of Shockwave Intravascular Lithotripsy (IVL) technology in calcified common femoral lesions in patients with peripheral artery disease for a series of endpoints, including target lesion revascularization and health status, to enable future planning of comparative effectiveness research.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Yale New Haven Health, New Haven, Connecticut
Conditions: Femoral Arterial Calcification, Peripheral Arterial Disease, Claudication, Critical Limb Ischemia
Register for Updates
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
NCT04045665
Recruiting
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their ba... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Western Connecticut Hospital Systems, Danbury, Connecticut
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
NCT05915013
Recruiting
The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
02/04/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Depressive Disorder, Major, Post Traumatic Stress Disorder
Register for Updates
Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
NCT04562389
Recruiting
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Smilow Cancer Hospital - New Haven, New Haven, Connecticut
Conditions: Myelofibrosis
Register for Updates
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449
Recruiting
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and then in combination with endocrine therapy. The study consists of two parts and a China and Japan monotherapy cohort. Part 1 includes dose escalation cohorts evaluating PF-07220060 as single agent or in combination with endocrine therapy or enzalutamide, as well as a food effect cohort and a DDI cohort Part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/02/2025
Locations: Smilow Cancer Hospital at Yale - New Haven, New Haven, Connecticut
Conditions: Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
Register for Updates
Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A
NCT05248594
Recruiting
We have developed a questionnaire to elucidate the dosing, frequency and indication for the use of emicizumab in patients with Hemophilia A (mild, moderate or severe) ages 0-3 years. We are also collecting data on any pre-, peri and post surgical practices while on emicizumab. More importantly, we are asking if pediatricians are planning to introduce factor 8 to children who are already on emicizumab for primary prophylaxis as well as how and when they are planning to do so. We hope that this da... Read More
Gender:
ALL
Ages:
36 months and below
Trial Updated:
01/31/2025
Locations: Connecticut Children's Hemophilia Treatment Center - Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Hemophilia A
Register for Updates
Craving Network Neurofeedback
NCT06426693
Recruiting
This project tests whether individuals with overweight or obesity and high craving can learn to change their brain response to food cues using neurofeedback, to impact their craving and eating behavior.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/30/2025
Locations: Yale MRRC Anlyan Center, New Haven, Connecticut
Conditions: Overweight or Obesity
Register for Updates
Pembrolizumab, Olaparib, and Temozolomide for People with Glioma
NCT05188508
Recruiting
This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment or came back after treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Hartford Healthcare Alliance (Data Collection Only), Hartford, Connecticut
Conditions: Glioma
Register for Updates
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
NCT04174157
Recruiting
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. The purpose of this registry is to assess the long term outcomes of patients with SMA in the c... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/30/2025
Locations: Connecticut Children's Medical Center, Farmington, Connecticut
Conditions: Spinal Muscular Atrophy (SMA)
Register for Updates